The broad-range cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) is known to induce both a G1 cell cycle arrest and apoptosis. The mechanism of UCN-01-induced apoptosis is largely unknown. We analysed the mechanism of cytotoxicity of UCN-01 in four established colon carcinoma cell lines. The cell lines SW48 and LS513 responded to UCN-01 treatment by undergoing apoptosis in a concentration-dependent manner while the cell lines HT-29 and WiDr were completely resistant. Apoptosis in LS513 and SW48 cell lines was concomitant with the suppression of Bcl-x L on mRNA and protein level. In contrast, in the apoptosis-resistant cell lines, Bcl-x L expression was not affected by UCN-01. Stable overexpression of the Bcl-x L protein abrogated UCN-01-triggered apoptosis, but only partially restored growth, indicating that both cell cycle arrest and apoptosis exert the anticancer effect in a coordinated manner. The inhibition of Akt phosphorylation did not correlate with the apoptotic phenotype. UCN-01 inhibited the activating STAT3 phosphorylations on Ser727 and, notably, on Tyr705, but STAT3 did not contribute to Bcl-x L expression in colon carcinoma cells. Moreover, we show for the first time that UCN-01 induces apoptosis by suppression of Bcl-x L expression. The inhibition of this pathway is a new aspect of cytotoxic and modulatory potential of UCN-01.
Introduction

7-Hydroxystaurosporine (UCN-01) is a new antitumour agent that was isolated as a selective inhibitor of Ca
2 þ -and phospholipid-dependent protein kinase C (Takahashi et al., 1987) . It attracts particular attention due to two different properties as a chemotherapeutic agent: on the one hand, it modulates the effects of several wellknown chemotherapeutic agents at nontoxic concentrations and on the other, when applied at higher, therapeutic concentrations, it exerts intrinsic tumoricidal properties.
As a modulator, UCN-01 enhances the antitumour activity of several antitumour agents, including mitomycin C (Akinaga et al., 1993) , cisplatin (Bunch and Eastman, 1996; Husain et al., 1997) and 5-FU both in vitro (Abe et al., 2000) and in vivo (Koh et al., 2002) . The potentiation of cytotoxicity by UCN-01 is ascribed to its ability to abrogate the G2/M checkpoint Wang et al., 1996) , as previously reported for caffeine (Powell et al., 1995; Fan et al., 1997) . This checkpoint abrogation has been related to the direct inhibition of the Chk1 kinase by UCN-01, thereby resulting in defective activation of the cdc25C phosphatase and, consequently, the lack of inactivation of cdc2 kinase. Active cdc2 kinase leads to a premature and uncontrolled initiation of mitosis in cells with damaged and incompletely repaired DNA. This eventually results in a mitotic catastrophe. Moreover, p53 function in the DNA damage checkpoint does not require the presence of active Chk1 (Ahn et al., 2003) . Therefore, these effects seemed to indicate that the abrogation of G2/M arrest by UCN-01 can occur preferentially in p53-deficient cells, thus endowing UCN-01 with a specificity for killing p53-defective cells. Recent results suggest, however, that both Chk1 and Chk2 are inhibited by UCN-01 (Yu et al., 2002) , and that the G2/M abrogation may also occur in p53-intact cells (Hirose et al., 2001) .
The mechanisms of direct action of UCN-01 are less well understood. When administered as a single agent at micromolar concentrations, UCN-01 induces G0/G1 arrest or G2/M arrest, depending on cell type and defects in Rb pathway control (Dai et al., 2001) . UCN-01 directly inhibits the activating phosphorylation of CDK2 and CDK4 as well as the expression of both molecules (Kawakami et al., 1996) . Furthermore, UCN-01 induces the expression of CDK inhibitors p21 and p27 (Akinaga et al., 2000) . Both direct and indirect inhibition of CDKs by UCN-01 is associated with the decrease of phosphorylation of the retinoblastoma protein (pRb) and, eventually, with the accumulation of cells in the G1 phase (Kawakami et al., 1996) .
Along with cell cycle arrest, UCN-01 has been observed to induce apoptotic cell death in various lymphatic (Wang et al., 1995) , epithelial (Shao et al., 1997) and neuronal cells (Bredel et al., 1999) .
In contrast to cell cycle arrest, the mechanism of the apoptosis induction by UCN-01 is less well investigated. UCN-01 has been shown to induce apoptosis in a p53-independent manner (Husain et al., 1997; Shao et al., 1997; Mack et al., 1999; Nieves-Neira and Pommier, 1999; Byrd et al., 2001) . Since UCN-01 does not directly interact with DNA in both cell-free and cellular systems (Akinaga et al., 1991) , a mechanism that operates by targeting other molecules can be assumed. The direct molecular targets responsible for UCN-01-induced apoptosis, however, remain obscure.
The objective of the present study was therefore to investigate the mechanisms of UCN-01-mediated apoptosis in human colon carcinoma cell lines. Our data reveal that apoptosis is mediated through transcriptional suppression of the Bcl-x L protein.
Results
UCN-01-dependent triggering of apoptosis in colon carcinoma cell lines
Two pairs of colon carcinoma cells were selected that reacted differently to 48 h of UCN-01 treatment. Apoptosis was evaluated by nuclear staining of UCN-01-treated cells with DAPI and detection of apoptosisassociated nuclear condensation. The nuclear condensation was negligible in HT-29 and WiDr cells, but reached up to 50% in LS513 and SW48 cells at UCN-01 concentrations of 1 mM (Figure 1 ).
These data revealed two different apoptotic responses to UCN-01 between the two groups of colon carcinoma cells lines. We investigated the molecular changes associated with UCN-01-induced apoptosis.
In UCN-01-responsive cell lines Bcl-x L is transcriptionally suppressed and Bax/Bcl-x L protein ratio is increased
The antiapoptotic protein Bcl-x L was consistently downregulated only in the UCN-01-responsive but not in the non-responsive cell lines (Figure 2a and b) .
In contrast, the expression of the apoptotic protein Bax was not affected by the treatment with UCN-01 (Figure 2a and b) , while the expression of Bad was increased in SW48, WiDr and HT-29 and decreased in LS513 (Figure 2d ). The antiapoptotic protein Bcl-2 increased slightly in SW48 cell line, but was not detectable at all in LS513, HT-29 and WiDr cells (Figure 2d) .
The Bcl-x L protein is known to neutralize the apoptotic effect of the Bax protein, and the increase of the Bax/Bcl-x L ratio indicates the involvement of the mitochondrial pathway of apoptosis. Indeed poly(ADP) ribose polymerase (PARP) protein cleavage, which is a hallmark of apoptosis, was detectable in all experiments in which the Bax/Bcl-x L ratio increased at least twofold. The fraction of apoptotic cells visible by nuclear staining (40-50%, Figure 1b ) corresponds to the percentage of the overall PARP cleavage (40-50%, Figure 2a ). The suppression of Bcl-x L occurred already at 6 h, while significant PARP fragmentation was detectable at 8 h after the start of treatment, indicating that the suppression of Bcl-x L protein preceded the cleavage of PARP by at least 2 h (Figure 2c ), and thus supporting the hypothesis that the decrease of Bcl-x L expression contributes to apoptosis. In order to check if the RT-PCR clearly showed that Bcl-x L -mRNA was downregulated only in the cell lines that perform apoptosis after treatment (LS513, SW48), but remained constant in the nonresponsive cell lines (WiDr, HT-29) (Figure 3a) . Thus, and in agreement with recently reported data (Catlett-Falcone et al., 1999) , there was a concordance of the protein and mRNA change of Bcl-x L that were both downregulated upon UCN-01 treatment.
To further verify the RT-PCR results, we studied the effect of UCN-01 treatment on the Bcl-x L promoter by using a Bcl-x L promoter construct fused to a luciferase reporter gene. The UCN-01-responsive cell lines showed a significant decrease in luciferase activity, whereas in the apoptosis-resistant HT-29 cell line, the luciferase activity did not change. The apoptosis-resistant WiDr cell line showed an unexpected increase in the Bcl-x L promoter activity after treatment (Figure 3b ). When mRNA levels of Bcl-x L were analysed in the WiDr cells, however, no change of expression was evident (Figure 3a) .
Together, these data support the notion that UCN-01 induces the transcriptional suppression of Bcl-x L .
Overexpression of Bcl-x L interferes with UCN-01-induced apoptosis
To test if Bcl-x L is the key molecule responsible for UCN-01-dependent apoptosis or rather a member of an auxiliary pathway, we stably overexpressed Bcl-x L protein in LS513 cells by the use of a retroviral vector. A bulk culture of the Bcl-x L -transfected cells was more resistant to 48 h of treatment with 1000 nM Figure 4b ). The bulk transfectants may contain clones that do not express active Bcl-x L at all. Therefore clones overexpressing Bcl-x L were selected; they showed virtually no cleavage of PARP after UCN-01 treatment in comparison to selected mock clones, which showed a high percentage of cleaved PARP (Figure 4c ). This indicated that in colon carcinoma cells the Bcl-x L suppression is the essential factor determining the extent of UCN-01-induced apoptosis.
Akt, NF-kB, STAT3 are not involved in the differential regulation of Bcl-x L in response to UCN-01 treatment Bcl-x L has been previously shown to be activated by the Akt/PKB kinase (Sato et al., 2002) and through an NFkB-or STAT3-dependent pathway (Grad et al., 2000; Plowright et al., 2000) in different cell lines. Of those regulators, only Akt is known to be constitutively phosphorylated in colon carcinoma cell lines. Within 2 h after exposure to UCN-01, Akt phosphorylation at Ser473 was decreased to 20-40% of the control value in all cell lines, irrespective of their apoptotic behaviour (Figure 5, . This suggested that NF-kB and STAT3 belong to the class of latent transcription factors that normally are active only upon stimulation. Since there is a considerable basal expression of Bcl-x L in colon carcinoma cells, the responsible transcription factor must be constitutively active in the basal state and should be inhibited by UCN-01 in apoptosis-performing cells. The basal activity of the luciferase reporter with an NF-kB promoter was suppressed only in the SW48 cells, but in the remaining cell lines it was either unchanged (LS513) or increased (WiDr and HT-29) after UCN-01 treatment ( Figure 6 ). The UCN-01-induced change of transcription activity of NF-kB was thus inconsistent with the observation that in both former cell lines Bcl-x L was suppressed after UCN-01 treatment and argued against the involvement of NF-kB in the differential regulation of Bcl-x L after UCN-01 treatment.
For transcriptional activity of STAT3 both the dimerization-inducing phosphorylation at Tyr705 and the activating phosphorylation of Ser727 are necessary. We could detect phosphorylated Ser727 in all the investigated colon carcinoma cell lines in a basal state. This phosphorylation was partially inhibited by UCN-01 in the apoptosis-performing but not in the apoptosisresistant cell lines (Figure 7a) . The phosphorylation at Tyr705, however, was not detectable in the basal state in any of the cell lines investigated (data not shown). Tyr705 phosphorylation could be induced by stimulation with IFNa (Figure 7b ) or IL-6 (Figure 8a ) and then it was also inhibitable by UCN-01 (Figure 7b ). Thus UCN-01 is capable of inhibiting both phosphorylations of STAT3, but in the investigated colon carcinoma cells only one site is phosphorylated in the basal state.
To analyse if activated STAT3 can potentially regulate Bcl-x L expression in these cells, the SW48 cell line was transfected with the plasmid coding for the complete STAT3 protein and was treated with IL-6. The IL-6 stimulation induced Tyr705 phosphorylation of the exogenous STAT3 protein (Figure 8a ). Luciferase reporter assay of STAT3 activity indicated that the (Figure 8c ). Together, these data indicated that UCN-01 is able to inhibit STAT3 phosphorylation at Ser727 as well as at Tyr705, but that STAT3 was not regulating Bcl-x L in these colon carcinoma cell lines.
Cell growth inhibition by UCN-01 is determined by G1 cell cycle arrest and by apoptosis
To investigate the long-term effects of UCN-01-induced apoptosis on cell survival, we analysed the colonyforming ability of the parental LS513 cell line and of the Bcl-x L transfectants at an UCN-01 concentration of 1 mM (Figure 9 ).
The inhibition of apoptosis in LS513 cells by retroviral Bcl-x L overexpression increased the clonogenic survival of the clones 9 and 7 as compared to the parental (LS513) or mock-transfected (clone 3 and 12) cells (Figure 9a) . Surprisingly, the clonogenic growth of both Bcl-x L clones, which were not executing apoptosis, was still inhibited by treatment with 1 mM UCN-01. The low rate of colony formation by the apoptosis-deficient Bcl-x L clones 9 and 7 was probably due to a G1 arrest in these cells. Indeed, in the clones 3 or 12 transfected with empty vector, only about 45% of cells were in the G1 phase of the cell cycle while 25% executed apoptosis (Figure 9b ), and 70% of cells of Bcl-x L clone 9 ( Figure 9c ) and clone 7 (not shown) performed G1 arrest, which later gave rise to S phase cell cycle arrest. These data indicated that along with apoptosis the arrest in the G1 phase of the cell cycle is an important antiproliferative effect of UCN-01.
Discussion
We investigated the mechanism of UCN-01-induced apoptosis in colon carcinoma cell lines. This has not been hitherto clarified. We show here that transcriptional suppression of the Bcl-x L protein is the main factor contributing to apoptosis of the susceptible cells.
A slight (1.5-fold) decrease of Bcl-x L protein and apoptosis in HT-29 cells after UCN-01 treatment was reported previously (Shao et al., 1997; Chan et al., 2003) . The difference in susceptibility between the HT-29 cell line used by these authors and in the present work could be due to the inhomogeneity and variability of this cell line (Hanski et al., 1992) . The antiapoptotic protein Bcl-x L , which belongs to the Bcl-2 family of proteins (reviewed in Daniel et al., 2003) has been shown to be transcriptionally regulated by NF-kB (Lee et al., 1999; Chen et al., 2000) , and STAT3 (reviewed in Grad et al., 2000) . UCN-01 was also shown to induce apoptosis via the inhibition of protein kinase B/Akt (Sato et al., 2002) . We analysed, therefore, the effect of treatment on the Akt phosphorylation and on NF-kB and STAT3 activity.
Akt was a particularly interesting candidate since it is constitutively active in the basal state. It has recently been shown that UCN-01-mediated inhibition of the PDK1 kinase and the subsequent inactivation of Akt induces apoptosis in several cell lines, including mouse colon carcinoma (Sato et al., 2002) . In the present work, however, a similar decrease of Akt phosphorylation was observed after UCN-01 treatment in the apoptosisperforming as well as in the nonresponsive cell lines ( Figure 5 ). NF-kB transcriptional activity was suppressed in one apoptosis-performing cell line SW48, not significantly altered in the other cell line (LS513) and increased in both apoptosis-resistant cell lines (HT-29 and WiDr, Figure 6 ). This indicated that the difference in Bcl-x L response to UCN-01 is not due to differential activation of NF-kB. These data do not exclude the potential involvement of Akt and/or NF-kB in the regulation of Bcl-x L , but rule out their contribution to the differential apoptotic responses of the investigated cells to UCN-01 treatment.
Following external stimulation (e.g. by IFNa) STAT3 is phosphorylated at Tyr705, dimerizes and is translocated to the nucleus where it is further phosphorylated on Ser727. Both phosphorylation events are necessary for STAT3 activity as transcription factor. Our results with regard to the effects of UCN-01 on both activating phosphorylations of STAT3 indicate for the first time that, in addition to inhibiting serine-threonine kinases, UCN-01 might inhibit tyrosine kinases as well. Whether this is an indirect or direct effect of UCN-01 needs to be studied in more detail. Constitutive STAT3 activation and the associated high expression of Bcl-x L has been reported in prostate (Mora et al., 2002) , head and neck (Leong et al., 2003) , breast and ovarian carcinomas (Burke et al., 2001) , multiple myelomas (Plowright et al., 2000) and non-Hodgkin lymphomas (Alas and Bonavida, 2003) . The inhibition of STAT3 phosphorylation by piceatannol (Plowright et al., 2000) , tyrphostin (Burke et al., 2001) or of STAT3 expression by an inhibitory oligonucleotide (Leong et al., 2003) was associated with Bcl-x L suppression and increase of apoptosis in these cells. It is therefore likely that the cytostatic effect of UCN-01 in carcinomas with constitutively activated STAT3, for example, head and neck tumours (Patel et al., 2002 ) might be partly due to the inhibition of STAT3 phosphorylation and the resulting Bcl-x L suppression. Furthermore, the observed antiangiogenic effect of UCN-01 (Kruger et al., 1998) may also be due to the inhibition of STAT3, which was shown to mediate angiogenesis (Wei et al., 2003) . In the investigated colon cancer cell lines, however, we detected neither constitutive STAT3 Tyr705 phosphorylation nor the regulation of Bcl-x L by IL-6-activated STAT3.
The complete inhibition of the apoptotic pathway by Bcl-x L overexpression only partly increased the survival, the major inhibitory effect being due to the G1 as well as the S phase cell cycle arrest (Figure 9c ). This observation confirms and extends previous reports, indicating the critical role of G1 arrest for sensitivity of carcinoma cell lines to UCN-01 (Seynaeve et al., 1993; Wang et al., 1995; Kawakami et al., 1996; Akiyama et al., 1999a; Akiyama et al., 1999b; Mack et al., 1999; Sugiyama et al., 1999; Usuda et al., 2000) .
Together, the present data partly clarify not only the direct cytotoxic mechanism of UCN-01 but also some of its modulatory effects. It has been recently shown that for a large number of cytotoxic agents the level of Bcl-x L expression determines the apoptotic response to chemotherapy (Amundson et al., 2000) . The suppression of Bcl-x L leads to an increase of the Bax/Bcl-x L ratio, which in turn leads to an increase in the intracellular levels of Bax and ultimately to apoptosis via the mitochondrial pathway (von Haefen et al., 2002 (von Haefen et al., , 2003 Gillissen et al., 2003; ) . The present data suggest that UCN-01 may enhance the effects of other drugs by suppression of Bcl-x L level. This effect depends on the UCN-01-mediated inhibition of a hitherto unidentified transcriptional regulator of Bcl-x L . They suggest further that in tumours with constitutively activated STAT3, the UCN-01-mediated inhibition of this activation might contribute to apoptosis and to antiangiogenesis offering additional possibilities for the application of this drug. 
Materials and methods
Cell lines
Chemicals and treatment of cultured cells
In each experiment, cells were seeded 24 h before treatment. UCN-01 was diluted from a stock solution (8 mM in DMSO) in DMEM immediately before use. In all experiments cells were treated for 48 h with the drug at given concentration, unless indicated otherwise. All experiments were carried out at least three times.
Detection of apoptotic cells
Following treatment with increasing concentrations of UCN-01 for 48 h, the cells were trypsinized and pooled with the floating cells. Cytospins were made and nuclear staining was achieved by incubating the cells with DAPI (0.5 mg/ml in phosphate-buffered saline (PBS)) (Roche Molecular Biochemicals, Mannheim, Germany) for 10 min. The cytospins were coated with Fluoromount (Sigma, Taufkirchen, Germany) and coverslips were applied. Microscopic evaluation was carried out on an Olympus BX60F5 (Japan) using analySIS imaging software (Soft Imaging System, Muenster, Germany). A total of 200-300 cells were counted by at least two independent observers and the mean % of cells with condensed nuclei was determined.
Fragmentation of PARP was analysed using anti-PARP mouse monoclonal antibody (clone C2-10, Pharmingen, Heidelberg, Germany). For detection of PARP cleavage lysates were prepared as described from nontreated cells and cells treated for 48 h with up to 1 mM UCN-01.
Western blot analysis
At different concentrations and time points after treatment, adherent cells were scraped off and pooled with the floating cells. After washing with PBS, cell pellets were resuspended and lysed in lysis buffer described previously (Sato et al., 2002) for 15 min on ice. Lysates were precleared by centrifugation at 13 000 g for 30 min at 41C. Protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Munich, Germany). Protein (20 or 40 mg) were separated on SDS-polyacrylamide gels and electroblotted onto Immobilon-P membrane (Millipore, Eschborn, Germany). The membranes were blocked with 5% nonfat dry milk in 0.1% Tween-20 in TBS for 1 h, followed by overnight incubation at 41C with the corresponding first antibody. The following antibodies were employed: rabbit anti-BAX antibody (N20), goat anti-Akt1 antibody (C-20), mouse monoclonal anti-phosphotyrosine STAT3 antibody (clone B-7) (all from Santa Cruz Biotechnology, Heidelberg, Germany); mouse monoclonal anti-PARP antibody (clone C2-10), and mouse monoclonal anti-Bcl-x L (clone 2H12) (all from BD Pharmingen, Heidelberg, Germany); mouse monoclonal anti-b-actin antibody (clone AC-15) (Sigma-Aldrich Chemie, Taufkirchen, Germany). Rabbit anti-phospho-Akt antibody (Ser473; 9271S), rabbit anti-phosphoserine STAT3 antibody (Ser727; 9134S) and rabbit anti-STAT3 protein antibody were purchased from Cell Signaling, Frankfurt am Main, Germany. Mouse monoclonal anti-Bcl-2 antibody (bcl-2/100/D5) was purchased from Novacastra Laboratories Ltd, New Castle upon Tyne, UK.
Two peroxidase-conjugated second antibodies were used: goat anti-mouse (IgG þ IgM) or goat anti-rabbit IgG (Dianova, Hamburg, Germany). Detection was carried out using SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL, USA). Membranes were exposed to T-Mat Plus DG autoradiographic films (Kodak, Stuttgart, Germany). To assess the relative protein expression, the bands were scanned (GS-700 Imaging Densitometer, Bio-Rad Laboratories, Munich, Germany) and their intensity was compared to that of untreated samples. SD were calculated from at least three experiments.
Transfections and luciferase assays
The reporter plasmid pXP-Bcl-x Pr -Luc containing the Bcl-x L promoter from -109 to -975 bp was kindly provided by Dr Bouloukos (University of Nice, France). The reporter plasmid pNFkB-Luc containing four tandem copies of the NF-kB binding consensus sequence fused to a TATA-like promoter region from the herpes simplex virus thymidine kinase promoter was purchased from Clontech (Heidelberg, Germany). The reporter plasmid for STAT3 activity was described previously .
Each transfection experiment was carried out with 50 ng of the b-galactosidase construct as an internal standard and 500 ng of each plasmid (pXP-Bcl-x Pr -Luc or pXP1-Luc). Values are means of at least three independent experiments. The preparation of cell extracts and determination of luciferase activity in LUMAT LB 9501 (Berthold, Munich, Germany) was performed according to the supplemented recommendation. The activity of b-galactosidase was detected with the chemiluminescent reporter assay Galacto-Light Plus (Tropix, Bedford, MA, USA) according to the supplier's recommendations. The luciferase activity was normalized to that of b-galactosidase. The STAT3 expression plasmid was a kind gift from Dr Paul Coffer (Department of Pulmonary Diseases, University Medical Center, Utrecht, Netherlands). For analysis of STAT3 transcriptional activity, cells were cotransfected with 6 mg pSG5hSTAT3, 6 mg IFN-g reporter gene (3 Â Ly6E-GAS-Luc, a gift from Dr U Vinkemeier, Research Institute of Molecular Pharmacology, Berlin, Germany) and 0.6 mg phRL-TK-Luc with the calcium phosphate co-precipitation method. Following transfection, the cells were treated with IL-6 (25 ng/ ml) for different time periods. Luciferase activity assay was performed using the Dual-Luciferase reporter assay system (Promega Corporation, Mannheim, Germany) using manufacturer's instructions.
Analysis of Bcl-x L mRNA levels by RT-PCR Total RNA was isolated from nontreated and UCN-01-treated (1 mM for 48 h) cell lines using RNA Clean LS reagent (Hybaid, London, UK). RNA (25 ng) was used for RT-PCR using the OneStep RT-PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
The primers for Bcl-x L (forward: 5 0 -ACC CAT CCT GGC ACC TGG CA-3 0 ; and reverse: 5 0 -GGA TCC AAG GCT CTA GGT GG-3 0 ) were published previously (Yamit-Hezi et al., 2000) . The amplification was carried out for 25 cycles under the following conditions: denaturation 941C, 60 s; annealing 641C, 60 s; extension 721C, 60 s with a final extension at 721C for 5 min. b-actin was amplified as an internal control. The PCR products were electrophoresed on a 1.5% agarose gel containing ethidium bromide and visualized under UV light in a gel documentation system (Konrad Benda, Wiesloch, Germany).
Retroviral transfection
LS513 cells were stably transfected with empty retroviral vector (mock, pBabe-puro) or with a construct harbouring the Bcl-x L cDNA (p-Babe-puro-Bcl-x L ). Supernatant of the virus producing packing cell line FLYRD-18 (Cosset et al., 1995) was employed to infect LS513 cells in the presence of 8 mg/ml polybrene (Sigma, Gruenwald, Germany). Puromycin (1.25 mg/ml, Invitrogen, Karlsruhe, Germany) was added 48 h later. After six rounds of selection in the medium containing puromycin, overexpression of Bcl-x L was confirmed by Western blot analysis of fresh cultures. To investigate the contribution of Bcl-x L in UCN-01-induced apoptosis, the cells were treated with increasing UCN-01 concentrations for a period of 24 h and then harvested for the analysis of PARP cleavage.
Clonogenic assay
A clonogenic assay was performed by seeding 100-250 cells into 22-mm Petri dishes in 4 ml of media. After 24 h, the cells were treated for 48 h with different concentrations of UCN-01, carefully washed and drug-free medium was added. Crystal violet stained colonies of at least 50 cells were scored visually after 10-12 days. The experiment was performed at least three times using triplicate cultures for each drug concentration.
Abbreviations p53 wt , p53 wild type; p53 mut , p53 mutated.
